Edition:
India

People: Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

23.49USD
20 Sep 2019
Change (% chg)

-- (--)
Prev Close
$23.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
18,511
52-wk High
$38.48
52-wk Low
$19.43

Gutch, Michael 

Dr. Michael Gutch Ph.D. is an Independent Director of Albireo Pharma Inc. Dr. Gutch has served as a member of our board of directors since November 2016. He served on Albireo Limited's board of directors from October 2015 to November 2016. Since April 2017, Dr. Gutch has served as the Chief Business Officer and Chief Financial Officer of Entasis Therapeutics, a biotechnology company. From January 2014 to March 2017, he served as Executive Director of Corporate Development and Head of Equities at AstraZeneca, a global biopharmaceutical company. Dr. Gutch also served as Managing Director, Medimmune Ventures, the corporate venture capital arm of AstraZeneca from September 2011 to December 2013. Dr. Gutch served as Investment Director, HIG BioVentures of the investment firm HIG Capital from February 2008 to September 2011. Dr. Gutch has previously served as a Director of numerous private biotechnology companies and nonprofit organizations. Dr. Gutch holds an MBA in Finance from Indiana University and a Ph.D. in Molecular Pathology from SUNY Stony Brook. He earned his Bachelor's degrees in Biology and Chemistry from Alfred University.

Basic Compensation

Total Annual Compensation, USD 57,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 127,584
Fiscal Year Total, USD 185,084

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Chiswell

195,084

Ronald Cooper

3,618,630

Simon Harford

--

Jan Mattsson

1,404,280

Martha Carter

1,243,480

Patrick Horn

--
As Of  31 Dec 2018